CO6680609A2 - Composición acuosa que contiene bromhexina - Google Patents

Composición acuosa que contiene bromhexina

Info

Publication number
CO6680609A2
CO6680609A2 CO13004940A CO13004940A CO6680609A2 CO 6680609 A2 CO6680609 A2 CO 6680609A2 CO 13004940 A CO13004940 A CO 13004940A CO 13004940 A CO13004940 A CO 13004940A CO 6680609 A2 CO6680609 A2 CO 6680609A2
Authority
CO
Colombia
Prior art keywords
composition containing
aqueous composition
containing bromhexine
bromhexine
composition
Prior art date
Application number
CO13004940A
Other languages
English (en)
Inventor
Uwe Scheuring
Bernd Plohmann
Annette Zamponi
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43063562&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6680609(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CO6680609A2 publication Critical patent/CO6680609A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

La presente invención se refiere a una composición acuosa que contiene bromhexina, en donde la composición tiene una cantidad de azúcar-alcoholes interior a 10 g referida a 100 ml de a composición y a su empleo para a terapia secretórica en enfermedades broncopulmonares agudas y crónicas.
CO13004940A 2010-07-12 2013-01-11 Composición acuosa que contiene bromhexina CO6680609A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10169236 2010-07-12

Publications (1)

Publication Number Publication Date
CO6680609A2 true CO6680609A2 (es) 2013-05-31

Family

ID=43063562

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13004940A CO6680609A2 (es) 2010-07-12 2013-01-11 Composición acuosa que contiene bromhexina

Country Status (26)

Country Link
US (1) US9220693B2 (es)
EP (1) EP2593094B1 (es)
JP (1) JP5979763B2 (es)
KR (1) KR101943812B1 (es)
CN (1) CN103052384B (es)
AR (1) AR082381A1 (es)
AU (1) AU2011278451B2 (es)
BR (1) BR112013000537B1 (es)
CA (1) CA2803471C (es)
CL (1) CL2012003625A1 (es)
CO (1) CO6680609A2 (es)
CY (1) CY1120079T1 (es)
DK (1) DK2593094T3 (es)
EA (1) EA025640B1 (es)
EC (1) ECSP13012384A (es)
ES (1) ES2661973T3 (es)
HR (1) HRP20180396T1 (es)
HU (1) HUE038399T2 (es)
LT (1) LT2593094T (es)
MX (1) MX337454B (es)
PE (1) PE20131063A1 (es)
PL (1) PL2593094T3 (es)
PT (1) PT2593094T (es)
SG (1) SG187016A1 (es)
SI (1) SI2593094T1 (es)
WO (1) WO2012007352A1 (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5979763B2 (ja) 2010-07-12 2016-08-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ブロムヘキシンを含む水性組成物
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
WO2013168021A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
JP2015519333A (ja) 2012-05-07 2015-07-09 セリックスビオ プライヴェート リミテッド 神経疾患の治療のための組成物および方法
US9309233B2 (en) 2012-05-08 2016-04-12 Cellix Bio Private Limited Compositions and methods for the treatment of blood clotting disorders
WO2013167993A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
CA2873104A1 (en) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions and methods for the treatment of mucositis
EP2852569B1 (en) 2012-05-23 2020-10-14 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
CA2873096A1 (en) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
US9670153B2 (en) 2012-09-08 2017-06-06 Cellix Bio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
JP6017249B2 (ja) * 2012-09-28 2016-10-26 小林製薬株式会社 経口投与用液体医薬組成物
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
CA2914461A1 (en) 2013-06-04 2014-12-11 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
CN103893116B (zh) * 2014-04-17 2015-12-09 河北仁合益康药业有限公司 一种盐酸溴己新口服液组合物
ES2873078T3 (es) * 2014-05-23 2021-11-03 Sanofi Aventis Deutschland Jarabe para la tos que contiene hidrocloruro de ambroxol
SG11201706952VA (en) 2014-09-26 2017-10-30 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
CA2967908C (en) 2014-09-29 2020-11-17 Mahesh Kandula Compositions and methods for the treatment of multiple sclerosis
JP6564868B2 (ja) 2014-10-27 2019-08-21 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 多発性硬化症の治療のための、フマル酸モノメチルエステルとピペラジン又はエチレンジアミンとの３つの成分の塩
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CA2973178C (en) 2015-01-06 2022-11-01 Cellix Bio Private Limited Bupivacaine derivatives and their use in the treatment of inflammation and pain
CN111568861A (zh) * 2020-05-25 2020-08-25 河北科星药业有限公司 畜禽用盐酸溴己新口服液及其制备方法和应用
CN111714477B (zh) * 2020-07-23 2021-06-15 山东迅达康兽药有限公司 祛痰组合物及其口服液制备方法
CN113109463B (zh) * 2021-03-16 2022-11-25 浙江工业大学 一种复方氯丙那林溴己新胶囊中有关物质的检测方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH085784B2 (ja) 1987-06-17 1996-01-24 興和株式会社 シロツプ剤
US5624906A (en) * 1994-12-08 1997-04-29 Lever Brothers Company, Division Of Conopco, Inc. Oral hygiene compositions comprising heteroatom containing alkyl aldonamide compounds
CA2253260A1 (en) * 1996-05-02 1997-11-13 Taisho Pharmaceutical Co., Ltd. Suspension of sparingly water-soluble acidic drug
JP3800437B2 (ja) 1996-07-24 2006-07-26 大正製薬株式会社 苦味が軽減された液剤
JPH10101581A (ja) 1996-09-26 1998-04-21 Taisho Pharmaceut Co Ltd 塩酸ブロムヘキシンの安定化製剤及び安定化方法
JPH10306038A (ja) 1997-05-07 1998-11-17 Taisho Pharmaceut Co Ltd ブロムヘキシン含有液剤
JP2000281562A (ja) * 1999-03-30 2000-10-10 Taisho Pharmaceut Co Ltd ゲル状組成物
JP2001106639A (ja) * 1999-10-04 2001-04-17 Taisho Pharmaceut Co Ltd 経口用組成物
EP1121940A1 (en) * 2000-01-31 2001-08-08 New Pharma Research Sweden AB Pharmaceutical compositions comprising an antibiotic and bromhexine, and process for their preparation
JP2002081562A (ja) 2000-09-05 2002-03-22 Kayaba Ind Co Ltd リリーフ弁
US6692725B2 (en) * 2001-02-19 2004-02-17 Daicel Chemical Industries, Ltd. Composition for oral care
US7138133B2 (en) * 2001-10-10 2006-11-21 The Procter & Gamble Company Orally administered liquid compositions
JP5134802B2 (ja) 2005-09-29 2013-01-30 第一三共ヘルスケア株式会社 塩酸ブロムヘキシン含有量低下の防止方法
US10022339B2 (en) * 2006-04-21 2018-07-17 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
JP2008013542A (ja) * 2006-06-07 2008-01-24 Daiichi Sankyo Healthcare Co Ltd 去痰又は気道杯細胞過形成抑制のための医薬組成物
CN100409835C (zh) * 2007-04-06 2008-08-13 张嵩 含有溴己新盐的组合物及大容量注射剂和注射剂制备方法
KR101025498B1 (ko) * 2008-05-02 2011-03-31 (주)이엘티사이언스 염산브롬헥신 경구용 액제 복합조성물 및 그 제조방법
JP5979763B2 (ja) 2010-07-12 2016-08-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ブロムヘキシンを含む水性組成物

Also Published As

Publication number Publication date
MX337454B (es) 2016-03-07
EP2593094A1 (de) 2013-05-22
WO2012007352A1 (de) 2012-01-19
SI2593094T1 (en) 2018-04-30
AU2011278451B2 (en) 2014-11-27
CY1120079T1 (el) 2018-12-12
BR112013000537A2 (pt) 2016-05-24
PT2593094T (pt) 2018-03-12
LT2593094T (lt) 2018-03-26
DK2593094T3 (en) 2018-03-12
JP2013531017A (ja) 2013-08-01
MX2013000417A (es) 2013-02-07
US9220693B2 (en) 2015-12-29
CA2803471A1 (en) 2012-01-19
CN103052384A (zh) 2013-04-17
EA201201659A1 (ru) 2013-06-28
AU2011278451A1 (en) 2013-01-24
JP5979763B2 (ja) 2016-08-31
CL2012003625A1 (es) 2013-05-31
ECSP13012384A (es) 2013-03-28
BR112013000537B1 (pt) 2021-07-27
KR20130100091A (ko) 2013-09-09
KR101943812B1 (ko) 2019-01-31
ES2661973T3 (es) 2018-04-04
AR082381A1 (es) 2012-12-05
HUE038399T2 (hu) 2018-10-29
SG187016A1 (en) 2013-02-28
PL2593094T3 (pl) 2018-05-30
EA025640B1 (ru) 2017-01-30
PE20131063A1 (es) 2013-10-12
CA2803471C (en) 2019-01-15
CN103052384B (zh) 2017-04-05
HRP20180396T1 (hr) 2018-04-20
EP2593094B1 (de) 2017-12-06
US20130267605A1 (en) 2013-10-10

Similar Documents

Publication Publication Date Title
CO6680609A2 (es) Composición acuosa que contiene bromhexina
CL2016000373A1 (es) Beneficio de supervivencia en pacientes con tumores sólidos con niveles elevados de proteína c reactiva
CL2012000620A1 (es) Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20.
MY173148A (en) Platelet lysate gel
BR112016000489A2 (pt) composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
BR112015021521A2 (pt) anticorpos anti-crth2 e métodos para seu uso
EA201490559A1 (ru) Композиция для лечения свища
PH12015501071A1 (en) Combination therapy of anti-her3 antibodies
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112015030268A2 (pt) composição farmacêutica, recipiente, kit, e, método para a preparação de uma composição
BR112012026707A2 (pt) uso de um anticorpo anti-cd20 afucosilado, composição que compreende um anticorpo anti-cd20 afucosilado e método de tratamento de pacientes que sofrem de câncer por meio da administração de um anticorpo anti-cd20 afucosilado
TWD168530S (zh) 容器
EA201200484A1 (ru) Фармацевтическая композиция с действующими веществами - метформином и ситаглиптином или вилдаглиптином
TWD189563S (zh) 鼻管組件
BR112013002441A2 (pt) uso de um anticorpo anti-cd20 afucosilado, composição e método de tratamento de paciente que sofre de câncer
AR095583A1 (es) Recipiente que tiene un indicador de uso
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
BR112013000840A2 (pt) método para aumentar o efeito de forma ativada potencializada de anticorpo para molécula endógena biológica, composição farmacêutica e uso de combinação de molécula biológica endógena com forma ativada potencializada de anticorpo para a sintase no endotelial.
EA201491300A1 (ru) Композиция для назального применения с улучшенной стабильностью
AR091888A1 (es) Compuestos de urea y su uso como inhibidores de enzimas
BR112012015449A2 (pt) suspensão de monoidrato de calcipotriol, monoidrato de calcipotriol, processo para preparar nanocristais de monoidrato de calcipotriol, e, composição farmacêutica
BR112015031623A2 (pt) grânulos com núcleos lisos pequenos
BR112015017432A2 (pt) métodos para o tratamento de indicações cardiovasculares
CL2015003460A1 (es) Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica
BR112015004494A2 (pt) célula de fluxo de permeabilidade e sistema de condutância hidráulica

Legal Events

Date Code Title Description
FC Application refused